These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 11747330

  • 1. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
    Moch C, Moysan A, Lubin R, de la Salmonière P, Soufir N, Galisson F, Vilmer C, Venutolo E, Le Pelletier F, Janin A, Basset-Séguin N.
    Br J Cancer; 2001 Dec 14; 85(12):1883-6. PubMed ID: 11747330
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mutation spectra of epidermal p53 clones adjacent to basal cell carcinoma and squamous cell carcinoma.
    Bäckvall H, Strömberg S, Gustafsson A, Asplund A, Sivertsson A, Lundeberg J, Ponten F.
    Exp Dermatol; 2004 Oct 14; 13(10):643-50. PubMed ID: 15447725
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
    Ansarin H, Daliri M, Soltani-Arabshahi R.
    Eur J Dermatol; 2006 Oct 14; 16(5):543-7. PubMed ID: 17101476
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
    Schneider J, Presek P, Braun A, Bauer P, Konietzko N, Wiesner B, Woitowitz HJ.
    Br J Cancer; 1999 Aug 14; 80(12):1987-94. PubMed ID: 10471051
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
    Castelli M, Cianfriglia F, Manieri A, Palma L, Pezzuto RW, Falasca G, Delpino A.
    Anticancer Res; 2001 Aug 14; 21(1B):753-8. PubMed ID: 11299839
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Infrequent p53 mutations in arsenic-related skin lesions.
    Castrén K, Ranki A, Welsh JA, Vähäkangas KH.
    Oncol Res; 1998 Aug 14; 10(9):475-82. PubMed ID: 10223623
    [Abstract] [Full Text] [Related]

  • 16. A study of mitochondrial DNA D-loop mutations and p53 status in nonmelanoma skin cancer.
    Prior SL, Griffiths AP, Lewis PD.
    Br J Dermatol; 2009 Nov 14; 161(5):1067-71. PubMed ID: 19624548
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas.
    Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar A, Lippman SM, Kripke ML, Ananthaswamy HN.
    Clin Cancer Res; 2003 Jan 14; 9(1):228-34. PubMed ID: 12538474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.